Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

BridgeBio’s Cardiomyopathy Drug Candidate Falters in Phase 3 Study

BridgeBio’s Cardiomyopathy Drug Candidate Falters in Phase 3 Study

BridgeBio’s investigational cardiomyopathy molecule acoramidis (AG10) fell short of the phase 3 finish line last week, when it not only failed its primary endpoint, but was associated with decre...

Is energy the key to Alzheimer’s disease?

Is energy the key to Alzheimer’s disease?

A team of researchers at the University of Adelaide has found a link between the way that cells produce energy for brain function and the mutated genes found in Alzheimer's disease. ...

Omicron hospitalization risk lower than delta, vaccines provide good protection, U.K. study says

Omicron hospitalization risk lower than delta, vaccines provide good protection, U.K. study says

The U.K. Health Security Agency found the risk of hospitalization for people infected with omicron is about a third of that posed by the delta variant.

Samsung in talks to buy Biogen for $42bn

Samsung in talks to buy Biogen for $42bn

NEW YORK: Shares of Biogen surged Wednesday following a report that South Korean giant Samsung Group is in talks to acquire the US biotech company for more than $40 billion.